Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia. What are the Challenges? Journal Article

Authors: Davila, M. L.; Brentjens, R.
Article Title: Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia. What are the Challenges?
Abstract: Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL. Because adoptive transfer of CAR-modified T cells is a novel approach, there are issues for the medical oncologist to consider when evaluating current and future clinical trials for CLL patients. This article reviews the impact of CAR design, T-cell production, T-cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T-cell infusion on the efficacy of this therapy. © 2013 Elsevier Inc..
Keywords: signal transduction; cancer chemotherapy; treatment response; review; nonhuman; clinical trials as topic; drug megadose; outcome assessment; binding affinity; protein domain; antigen expression; lymphocyte proliferation; t-lymphocytes; animals; tumor volume; bendamustine; cyclophosphamide; antineoplastic activity; chimera; minimal residual disease; tumor burden; recombinant proteins; adoptive cell therapy; chimeric antigen receptor; adoptive transfer; gamma irradiation; electroporation; cytokine production; immunophenotyping; drug cytotoxicity; cancer control; cytokine release; leukemia relapse; chronic lymphatic leukemia; immunotherapy, adoptive; t lymphocyte activation; lymphocytopoiesis; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; leukemia, lymphocytic, chronic, b-cell; receptors, antigen; lymphocyte count; pentostatin; leukemia remission; cancer gene therapy; chronic lymphocytic leukemia; cd19; cancer prognosis; cell engineering
Journal Title: Hematology/Oncology Clinics of North America
Volume: 27
Issue: 2
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2013-04-01
Start Page: 341
End Page: 353
Language: English
PROVIDER: scopus
PMCID: PMC3615434
PUBMED: 23561477
DOI: 10.1016/j.hoc.2012.12.004
Notes: --- - "Export Date: 1 May 2013" - "CODEN: HCNAE" - ":doi 10.1016/j.hoc.2012.12.004" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Renier J Brentjens
    274 Brentjens
  2. Marco Luis Davila
    24 Davila